Nisa Investment Advisors LLC Increases Position in DaVita Inc. (NYSE:DVA)

Nisa Investment Advisors LLC increased its stake in shares of DaVita Inc. (NYSE:DVA) by 26.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,694 shares of the company’s stock after buying an additional 7,752 shares during the quarter. Nisa Investment Advisors LLC’s holdings in DaVita were worth $5,085,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of DaVita by 2.4% during the fourth quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock valued at $662,161,000 after buying an additional 145,711 shares during the last quarter. Gates Capital Management Inc. grew its holdings in shares of DaVita by 3.1% during the fourth quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock valued at $94,895,000 after buying an additional 27,660 shares during the last quarter. 8 Knots Management LLC purchased a new stake in shares of DaVita during the fourth quarter valued at $89,504,000. Allianz Asset Management GmbH grew its holdings in shares of DaVita by 63.9% during the fourth quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after buying an additional 213,992 shares during the last quarter. Finally, Doma Perpetual Capital Management LLC purchased a new stake in DaVita in the fourth quarter valued at $53,076,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DaVita

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the sale, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. The disclosure for this sale can be found here. 2.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Barclays upped their price target on shares of DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a report on Monday, May 6th. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. TD Cowen upped their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Truist Financial upped their price objective on shares of DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $154.00.

DaVita Stock Up 1.2 %

DVA opened at $152.17 on Tuesday. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $152.22. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The company has a 50-day moving average price of $140.53 and a 200 day moving average price of $135.42. The company has a market cap of $13.35 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 0.86 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. During the same quarter in the prior year, the firm earned $2.08 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. Sell-side analysts expect that DaVita Inc. will post 9.9 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.